Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06366087 · ClinicalTrials.gov registry record · Phase 1
Sublingual Atropine Bioequivalence by Route of Administration (SABER)
A Phase 1 study, sponsored by Biomedical Advanced Research and Development Authority.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT06366087 is a Phase 1 study that has completed, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 46 participants.
The verdict
NCT06366087, a Phase 1 study, has completed, sponsored by Biomedical Advanced Research and Development Authority.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
A randomized, two-period, two-sequence, crossover study to assess the bioequivalence, bioavailability, and pharmacokinetics (PK) of a single dose of atropine administered sublingually (SL) or intramuscularly (IM) in healthy adult volunteers.
Interventions
- DRUG Atropine Sulfate Ophthalmic Solution USP, 1%
- DRUG Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06366087
The ClinicalTrials.gov registry entry for NCT06366087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atropine Sulfate Ophthalmic Solution USP, 1% is the first listed.
NCT06366087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06366087 about?
NCT06366087 is a clinical study titled "Sublingual Atropine Bioequivalence by Route of Administration (SABER)". A randomized, two-period, two-sequence, crossover study to assess the bioequivalence, bioavailability, and pharmacokinetics (PK) of a single dose of atropine administered sublingually (SL) or intramuscularly (IM) in healthy adult volunteers.
What is the current status of trial NCT06366087?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-04-15. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT06366087?
The interventions under investigation include: Atropine Sulfate Ophthalmic Solution USP, 1% (DRUG), Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) (DRUG).
Who is sponsoring clinical trial NCT06366087?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.